申请人:GLAXO GROUP LIMITED
公开号:EP0330469A2
公开(公告)日:1989-08-30
Disclosed are compounds of formula (I) :
wherein
R₁ represents hydroxy or C₁₋₆ alkoxy;
R₂ and R₃ are the same or different and are C₁₋₆ alkyl or C₃₋₆ alkenyl or -NR₂R₃ represents a 5-membered (optionally containing an oxygen atom adjacent to the nitrogen) or a 6-membered ring, which ring optionally contains one unit of unsaturation and which is unsubstituted or substituted by hydroxy, oxo, optionally substituted methylidene, -COR₄(where R₄ is C₁₋₆ alkyl, aryl or ar(C₁₋₆)alkyl) or =NOR₅ (where R₅ is C₁₋₆ alkyl);
X represents a direct bond, -CH₂- or -CH₂O;
Ar represents a substituted phenyl moiety
and physiologically acceptable salts thereof.
Also described are methods for their preparation and pharmaceutical formulations thereof. The compounds are Kappa agonists.
公开了式 (I) 的化合物:
其中
R₁ 代表羟基或 C₁₋₆ 烷氧基;
R₂ 和 R₃ 相同或不同,并且是 C₁₋₆ 烷基或 C₃₋₆ 烯基,或 -NR₂R₃ 代表 5 元环(可选含有与氮相邻的氧原子)或 6 元环、该环可选含有一个不饱和单元,且未被羟基、氧代取代或被羟基、氧代取代、任选取代的亚甲基、-COR₄(其中 R₄ 是 C₁₋₆ 烷基、芳基或 ar(C₁₋₆)烷基)或 =NOR₅(其中 R₅ 是 C₁₋₆ 烷基);
X 代表直接键、-CH₂- 或 -CH₂O;
Ar 代表取代的苯基
及其生理上可接受的盐类。
此外,还描述了它们的制备方法及其药物制剂。这些化合物是 Kappa 激动剂。